Biotech: Page
-
Michael M. Santiago via Getty Images
GPCR drugmaker Septerna amasses $288M in IPO
Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
By Gwendolyn Wu • Oct. 24, 2024 -
Permission granted by BIO
Q&A // Emerging biotechJ&J’s Asish Xavier on biotech’s rebound in a volatile era
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
By Gwendolyn Wu • Oct. 24, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Getty Images
Alto hits new low as depression drug flunks key test
While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s shares were down by two-thirds Wednesday morning.
By Jacob Bell • Oct. 23, 2024 -
Getty Images
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy.
By BioPharma Dive staff • Oct. 23, 2024 -
Permission granted by Editas Medicine
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its treatment reni-cel.
By Ned Pagliarulo • Oct. 22, 2024 -
Getty Images
Otsuka’s startup bet pays off with kidney disease drug results
A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
By Ben Fidler • Oct. 22, 2024 -
Getty Images
Deep Dive // State of PlayRNA editing: emerging from CRISPR’s shadow
Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
By Ben Fidler , Gwendolyn Wu • Oct. 22, 2024 -
Permission granted by PureTech Health
Q&A // Emerging biotechPureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
By Jacob Bell • Oct. 21, 2024 -
Getty Images
Brain drug developer Seaport raises another $225M
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
By Jacob Bell • Oct. 21, 2024 -
Getty Images
Sponsored by AltasciencesPharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Oct. 21, 2024 -
Getty Images
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
By BioPharma Dive staff • Oct. 18, 2024 -
Getty Images
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
By Delilah Alvarado • Oct. 17, 2024 -
Getty Images
Forbion follows string of startup exits with $2.2B fundraise
The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.
By Delilah Alvarado • Oct. 15, 2024 -
Getty Images
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.
By BioPharma Dive staff • Oct. 15, 2024 -
Getty Images
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.
By BioPharma Dive staff • Oct. 11, 2024 -
Getty Images
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.
By Gwendolyn Wu • Oct. 10, 2024 -
Getty Images
Purespring raises $105M to advance gene therapy for kidney disease
The Series B round will fund a Phase 1/2 trial of the company’s experimental treatment for IgA nephropathy.
By Delilah Alvarado • Oct. 9, 2024 -
Getty Images
Lilly partners with AI specialist Insitro to develop metabolic medicines
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
By Kristin Jensen • Oct. 9, 2024 -
Getty Images
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.
By BioPharma Dive staff • Oct. 9, 2024 -
Permission granted by Basecamp Research
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
By Gwendolyn Wu • Oct. 9, 2024 -
Permission granted by City Therapeutics
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
By Ned Pagliarulo • Oct. 8, 2024 -
Permission granted by Intellia Therapeutics
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
By Ned Pagliarulo • Oct. 7, 2024 -
Permission granted by Judo Bio
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
By Gwendolyn Wu • Oct. 7, 2024 -
Courtesy of Editas Medicine
Editas trades Vertex fees for upfront cash in DRI deal
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.
By Delilah Alvarado • Oct. 4, 2024 -
Getty Images
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
By BioPharma Dive staff • Oct. 4, 2024
Previous
